Journal
GENETICS IN MEDICINE
Volume 23, Issue 2, Pages 415-420Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/s41436-020-00987-w
Keywords
SMA type; incidence; nusinersen; compound motor action potential (CMAP); outcome
Categories
Funding
- Biogen
Ask authors/readers for more resources
This study conducted a large-scale newborn screening program for spinal muscular atrophy in Taiwan and identified 21 patients, with 70% being SMA type 1. The changes in CMAP amplitude in newborns could predict symptom onset and affect treatment outcomes.
Purpose Early identification and treatment of spinal muscular atrophy (SMA) are crucial but difficult. In this study, we aimed to assess the significance of compound motor action potential (CMAP) amplitude in patients identified through a newborn screening program. Methods We initiated a large-scale population newborn screening program for SMA in Taiwan in 2014. Patients had access to treatment through clinical trials or expanded use programs. Symptomatic patients were evaluated regularly, including CMAP exams. Results Among 364,000 screened newborns, 21 were diagnosed with SMA. The incidence of SMA was around 1 in 17,000 live births, and 70% developed SMA type 1. All infants with twoSMN2copies became symptomatic before the age of 1 month. CMAP amplitudes of 12 newborns were available, including 6 who were subsequently treated with nusinersen. We found that a rapid decrease of CMAP amplitude was an early predictor of symptom onset. Pretreatment CMAP and rapid increment of post-treatment CMAP could predict better treatment outcomes. Conclusion This study prospectively demonstrated the incidence of SMA and its types. Our results imply the importance of pretreatment CMAP amplitude and rapid reversal of post-treatment CMAP amplitude with regard to disease presentation and also treatment outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available